Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mediastinal (thymic) large B-cell lymphoma: where do we stand?

Thomas F E Barth1, Frank Leithäuser, Stefan Joos

  • 1Department of Pathology, University of Ulm, German.

The Lancet. Oncology
|June 18, 2002
PubMed
Summary

Mediastinal (thymic) B-cell lymphoma (MBL) is an aggressive tumor with unique features distinguishing it from other large B-cell lymphomas. Further research is needed to fully understand its origins and improve treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Haematologica·2026
Same author

[Modern systemic treatment-bispecific antibodies and CAR-T cell therapy : Clinical management, mechanisms of action, outcomes].

Radiologie (Heidelberg, Germany)·2025
Same author

Iron metabolism in a mouse model of hepatocellular carcinoma.

Scientific reports·2025
Same author

Refinement of the prognostic impact of somatic <i>CEBPA</i> bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG).

HemaSphere·2024
Same author

Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Pancreatic Cancer in Germany.

Oncology research and treatment·2024
Same author

Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study.

HemaSphere·2023

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Mediastinal (thymic) B-cell lymphoma (MBL) is a rare, aggressive tumor.
  • Its low incidence initially hindered detailed characterization.
  • MBL possesses distinct clinical, morphological, immunological, and genetic features.

Purpose of the Study:

  • To review current data on MBL.
  • To emphasize its unique properties.
  • To discuss recent advances in molecular genetics, biology, and treatment.

Main Methods:

  • Literature review of MBL cases.
  • Analysis of morphological, immunological, and genetic data.
  • Review of recent molecular genetics and treatment studies.

Related Experiment Videos

Main Results:

  • MBL is recognized as a distinct subtype of diffuse large B-cell lymphoma.
  • Its unique characteristics differentiate it from other B-cell lymphomas.
  • Significant insights into MBL biology and clinical aspects have emerged.

Conclusions:

  • MBL is a well-defined lymphoma subtype with unique characteristics.
  • The histogenesis of MBL requires further investigation.
  • Ongoing research continues to advance understanding and treatment of MBL.